Recently, a preliminary cohort study of patients on platinum-based regimens reported significantly less sensory neuropathy after chemotherapy in patients taking Ang-related drugs (AT1 receptor blockers or ACE inhibitors) compared with the control group [39], indicating that the neuroprotective effects of Ang-related drugs may be effective in CIPN. The gene discussed is ANG; the disease is sensory peripheral neuropathy.